Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.
When discussing the nation's ability to stomach orphan drug costs, an analyst has called the price tag "the straw that breaks the camel's back."
Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.
Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.
Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.
If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.
The drugmaker is planning a commercial boost for its HIV-prevention drug.
Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.
Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.
WPP will create "Team WBA," a bespoke team that would work on traditional and digital advertising, media, and PR.